Malin Corporation plc

MLC

IE00BVGC3741

Pharmaceuticals

Real-time Irish S.E. Other stock markets 11:55:00 2024-04-24 am EDT			5-day change	1st Jan Change
5.6 ^EUR	0.00%		0.00%	+24.44%

Mar. 28	Transcript : Malin Corporation plc - Shareholder/Analyst Call
Feb. 28	EARNINGS: Hutchmed revenue surges, Craven House's loss widens	AN

Malin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2020

March 23, 2021 at 04:23 am EDT

Malin Corporation plc announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was EUR 41 million compared to EUR 34.9 million a year ago. Operating loss was EUR 8.9 million compared to EUR 17.2 million a year ago. Net income was EUR 87.7 million compared to net loss of EUR 5.4 million a year ago.

Latest news about Malin Corporation plc

Transcript : Malin Corporation plc - Shareholder/Analyst Call	Mar. 28
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Tranche Update on Malin Corporation plc's Equity Buyback Plan announced on November 15, 2023.	Feb. 28	CI
Puma and Puma Alpha invest in Not Another Beer	Jan. 26	AN
Malin Corporation plc commences an Equity Buyback Plan, under the authorization approved on March 10, 2023.	Nov. 15	CI
Malin confirms new executive director joins board	23-10-27	AN
Malin Corporation plc Announces Board Changes	23-10-27	CI
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	23-10-03	MT
Malin Corporation plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-06	CI
Solid State sees strong orders in security & defence	23-09-06	AN
CG Oncology, Inc. announced that it has received $105 million in funding from a group of investors	23-08-01	CI
CG Oncology, Inc. announced that it expects to receive $105.019993 million in funding	23-07-26	CI
Malin CEO Darragh Lyons to resign before end of the year	23-07-05	AN
Malin CEO to Step Down at 2023-end	23-07-05	MT
Malin Corporation plc Announces CEO Changes	23-07-05	CI
Malin Corporation plc Announces Executive Changes	23-07-05	CI
Malin returns EUR140 million to shareholders through tender offer	23-03-21	AN
Tranche Update on Malin Corporation plc's Equity Buyback Plan announced on February 16, 2023.	23-03-21	CI
Malin Corporation plc's Equity Buyback announced on February 16, 2023, has closed with repurchase of 15,053,763 shares, representing 44.25% for €140 million.	23-03-19	CI
Transcript : Malin Corporation plc - Shareholder/Analyst Call	23-03-10
Transcript : Malin Corporation plc - Shareholder/Analyst Call	23-03-10
UK shareholder meetings calendar - next 7 days	23-03-03	AN
Malin confident heading into 2023; proposes investor return	23-02-16	AN
Malin to return up to EUR140 million to shareholders	23-02-16	AN
Malin Starts Tender Offer for Shares	23-02-16	MT

Chart Malin Corporation plc

Duration

Period

More charts

Company Profile

Malin Corporation Plc is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential.

Sector

Pharmaceuticals

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.6 EUR

Average target price

11.7 EUR

Spread / Average Target

+109.02%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MALIN CORPORATION PLC	+24.44%	113M
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.59%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.62%	219B
ROCHE HOLDING AG	-9.04%	196B
NOVARTIS AG	+6.50%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals